Somatorelin - Bausch Health Companies
Alternative Names: GRF 1-44; Growth hormone releasing factor (1-44); SomatoliberinLatest Information Update: 19 Jul 2018
At a glance
- Originator Fujisawa
- Developer Bausch Health Companies; Roche
- Class Amino acids; Hormones; Peptides
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Muscular atrophy; Somatotropin deficiency
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 15 Feb 1999 Phase-I clinical trials for Muscle wasting in Switzerland (Implant)
- 13 Nov 1997 Phase-II clinical trials for Muscle wasting in Yugoslavia (Parenteral)